Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
- Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)síndromes mielodisplásicas mds avanços na biologia terapias inovadoras epidemiologia da mds - Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.oncologia ccr câncer renal tki sunitinibe - Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.pomalidomide-dexamethasone rrmm management progression-free survival combination therapies - Transplant15m 53s
Profilaxia de CMV em receptores de transplantes
Conheça as estratégias de profilaxia de CMV no pós-transplante de órgãos sólidos, melhor forma de manejo e monitorização de viremia.cmv hospitalar valganciclovir antiviral manejo de viremia transplante - Mieloma múltiplo10m 40s
Recommendations -Management of Myeloma Related Renal Impairment
Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.myeloma renal impairment lancet guidelines - Mieloma múltiplo7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.minimum residual disease (mrd) mrd negativity multiple myeloma - Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromeslow risk mds venetoclax viale -a eln classification low dose lenalidomide tags: azacitidine - Câncer de próstata11m 38s
Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer
PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.treatment intensification mhspc triplet therapy peace-1 clinical trial - Acute Myeloid Leukaemia12m 22s
EHA 2022 Updates : AML
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone.aml decitabine g-csf hypomethylating agents - Oncospecials6m 24s
2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients
Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.2nd generation tki deep molecular response elts high risk e14a2 transcripts
- 1
Desenvolvimento e Atualizações na Biologia das...
- 2
A Relevância dos Agentes TKI na era das...
- 3
Integrating Pomalidomide Based Regimens in Multiple...
- 4
Profilaxia de CMV em receptores de transplantes
- 5
Recommendations -Management of Myeloma Related...
- 6
MRD Assesment in Multiple Myeloma -Ready for Prime...
- 7
ASH 2022 Update on Myelodysplastic Syndromes
- 8
Treatment Intensification in Metastatic Castration...
- 9
EHA 2022 Updates : AML
- 10
2nd Genenration TKIs for 1st line CP-CML -Selecting...